CD19 and B-cell non-Hodgkin lymphoma: A further study suggested that 21D4 CAR-T cells exert antitumor activity against B-cell lymphoma with CD19 exon 1 and 2 mutations, which are associated with resistance to FMC63 CAR-T cells (10).